Leclercia Adecarboxylata Causing Necrotizing Fasciitis in an Immunocompetent Athlete Injecting Illicit Testosterone Supplements

Milan Kaushik¹, Aayush Mittal¹, Kathleen Tirador¹, Hanan Ibrahim², Sean Drake²

1. Internal Medicine, Wayne State University School of Medicine, Detroit, USA 2. Internal Medicine, Henry Ford Health System, Detroit, USA

Corresponding author: Milan Kaushik, mkaushik@med.wayne.edu

Abstract

Leclercia adecarboxylata (L. adecarboxylata) is an uncommon and often misdiagnosed cause of multiple infection types including skin and soft tissue, cholecystitis, and septicemia. It commonly afflicts immunocompromised hosts or individuals who experience trauma in aquatic environments. We present a case where this bacteria causes necrotizing fasciitis as a consequence of injecting street bought testosterone supplements. This patient was treated successfully with excisional debridement of the wound as well as a one week course of Linezolid and Bactrim.

Categories: Internal Medicine, Infectious Disease, Public Health

Keywords: leclercia adecarboxylata, necrotizing fasciitis, bacterial infection, herbal supplements, testosterone, illicit drugs, immunocompetent, rare pathogen, injection drug use, soft tissue infection

Introduction

Leclercia adecarboxylata (L. adecarboxylata) is a rare, opportunistic gram-negative rod generally associated with cutaneous infections following aquatic exposures [1]. Here, we describe a case of an immunocompetent female who injected herself with an illicit steroid herbal combination for muscle growth. To our knowledge, this is the first case report of the emerging L. adecarboxylata causing necrotizing fasciitis in the setting of intramuscular injection in an immunocompetent host.

Case Presentation

A 22-year-old female was admitted to the hospital due to significant right hip pain. As an aspiring boxer, she had been injecting herself with a combination of testosterone and herbal supplements over the last six months to increase muscle mass. The patient states the drug combination and needles were both obtained from a street vendor. Two weeks prior to presentation, she developed redness surrounding the injection site and right hip pain which impaired her ambulation. She has a history of seizures on keppra, asthma, and schizoaffective disorder which required prior psychiatric hospital admission. She smokes five cigarettes daily and marijuana occasionally but denies any other drug use. In the emergency department, she had a temperature of 37.9 C, heart rate of 119, and normal blood pressure with labs notable for elevated C- reactive protein (CRP) of 19.5 mg/dL and erythrocyte sedimentation rate (ESR) of 79 mm/Hr but a normal white blood cell count. Her hip is demonstrated in Figure 1. Blood cultures were obtained and showed no growth. Preliminary ultrasound revealed edema and trace fluid in the right hip joint but CT Pelvis highlighted a possible uncontained gas-forming infection in the soft tissue, but no evidence of myositis, osseous infections, or hip joint involvement (Figure 2). After one day of treatment with Vancomycin and Zosyn, excisional debridement of the right hip subcutaneous tissue was performed (Figure 3). Pockets of gas, pus, and necrotic tissue were found down to the fascial level which were sent for culture. Rapid speciation identified many Leclercia adecarboxylata only resistant to ampicillin, Klebsiella pneumoniae, and Enterococcus casseliflavus. The patient was started on one week of double-strength Bactrim per os (PO) and one week of PO Linezolid 600 mg BID out of concern for vancomycin resistant enterococcus. The patient was monitored for five days following the procedure and was lost to follow up.

Review began 09/23/2020

Review ended 10/16/2020

Published 10/27/2020

© Copyright 2020

Kaushik et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Kaushik M, Mittal A, Tirador K, et al. (October 27, 2020) Leclercia Adecarboxylata Causing Necrotizing Fasciitis in an Immunocompetent Athlete Injecting Illicit Testosterone Supplements. Cureus 12(10): e11196. DOI 10.7759/cureus.11196

FIGURE 1: Patient's right hip on admission

FIGURE 2: CT Pelvis demonstrating free gas in the patient's right hip soft tissue

FIGURE 3: Postoperative incisions

Discussion

First discovered in 1962 as “*Escherichia Adecarboxylata* (*E.coli*),” this pathogen was described as a motile, gram-negative, oxidase-negative bacterium that shared many similar biochemical properties with *Escherichia Coli* [2]. Due to advancement in microbiology identification capabilities, there have been an increasing number of *L. adecarboxylata* infections diagnosed, primarily as an opportunistic pathogen. It has been hypothesized that certain cases of possible *L. adecarboxylata* infections may have previously been misdiagnosed as *E. coli* due to a lack of awareness surrounding the bacterium [3].

As we continue to advance our microbiology diagnostic abilities, *L. adecarboxylata* is of growing importance in clinical literature which indicates that infections have manifested as septicemia [4], peritonitis [5], posttraumatic polymicrobial wound/soft tissue infection [6], and cholecystitis [7]. Although typically seen as an opportunistic infection in immunocompromised individuals, there have been increasing reports of *L. adecarboxylata* present in immunocompetent hosts who suffer from trauma in aquatic environments [8]. We highlight the contraction from a self-inflicted injection in a non-aquatic environment. After the introduction from injection, our patient developed a polymicrobial gaseous and necrotic soft tissue infection in the right hip that required debridement.

The susceptibility tests of *L. adecarboxylata* cultured from our patient demonstrated resistance to Ampicillin. There have been reports of this organism developing New Delhi metallo- β -lactamase-1 (NDM-1) resistance, resulting in the ability to hydrolyze all β -lactams [9]. Although this patient was susceptible to other β -Lactam antibiotics, the development of Ampicillin resistance alone in an organism of growing prevalence leads to concern of future antibiotic resistance. The growth of *L. adecarboxylata* from culture drew concern for unregulated supplements as a new route for infection in immunocompetent hosts.

Select athletes elect to use performance-enhancing drugs which can either come from professional or personal laboratories, with the purity and contamination differing significantly. Although it is not possible to differentiate the quality of a product by its packaging, liquid chromatography and tandem mass spectrometry provide valuable insight. 25% of confiscated German black market drugs, including steroids, revealed impure or completely wrong components [10]. Many clandestine drug production operations have also been linked to integrating bacteria-contaminated water in their products [11]. Some users who obtained anabolic steroids from an illicit source were also more likely to engage in high-risk injection practices such as sharing multi-dose vials and dividing drugs using syringes [12]. These practices increase the risk of infection with organisms not classically associated with skin flora [13]. This is a possible explanation for our patient’s presentation with *L. adecarboxylata* infection following injections.

Conclusions

This case report highlights the case of an immunocompetent individual contracting *L. adedecarboxylata* as part of a polymicrobial gaseous and necrotizing soft tissue infection in a non-traumatic and non-aquatic environment. Our patient was injecting non-sterile testosterone and herbal supplements into her right thigh which introduced these bacteria, eventually resulting in a debilitating tissue infection requiring surgical intervention. This is the first case, to our knowledge, which demonstrates an infection with *L. adedecarboxylata* in an immunocompetent individual through this route.

As our patient purchased these supplements from a street vendor, this case raises questions regarding the safety of an unregulated market. Especially considering the resistance to ampicillin, there is concern for growth of newly resistant organisms. We hope this case brings to attention this new avenue for infection with *L. adedecarboxylata* in immunocompetent hosts and highlights the importance of screening for this organism. We believe that awareness regarding the clinical presentation and potential antibiotic resistance can assist in clinical care moving forward.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Spiegelhauer MR, Andersen PF, Frandsen TH, Nordestgaard R, Andersen LP : Leclercia adedecarboxylata: a case report and literature review of 74 cases demonstrating its pathogenicity in immunocompromised patients. *Infect Dis (Lond)*. 2018, 51:179-188. [10.1080/23744235.2018.1536830](https://doi.org/10.1080/23744235.2018.1536830)
2. Alosaimi RS, Muhmmmed Kaaki M: Catheter-related ESBL-producing leclercia adedecarboxylata septicemia in hemodialysis patient: an emerging pathogen?. *Case Rep Infect Dis*. 2020, 7403152: [10.1155/2020/7403152](https://doi.org/10.1155/2020/7403152)
3. Adapa S, Konala VM, Nawaz F, Javed T, Dhingra H, Gutierrez IA, Ramirez ML : Peritonitis from leclercia adedecarboxylata: an emerging pathogen. *Clin Case Rep*. 2019, 7:829-831. [10.1002/ccr3.2094](https://doi.org/10.1002/ccr3.2094)
4. Mauri AD, Chiarinotti D, Andreoni S, Molinari GL, Conti N, De Leo M: Leclercia adedecarboxylata and catheter-related bacteraemia: review of the literature and outcome with regard to catheters and patients. *J Med Microbiol*. 2013, 62:1620-1623. [10.1099/jmm.0.059535-0](https://doi.org/10.1099/jmm.0.059535-0)
5. Kim HM, Chon CY, Ahn SH, Jung SJ, Han KH, Moon BS, Moon YM : Fatal spontaneous bacterial peritonitis by leclercia adedecarboxylata in a patient with hepatocellular carcinoma. *Int J Clin Pract*. 2008, 62:1296-1298. [10.1111/j.1742-1241.2005.00780.x](https://doi.org/10.1111/j.1742-1241.2005.00780.x)
6. Forrester JD, Adams J, Sawyer RG: Leclercia adedecarboxylata bacteremia in a trauma patient: case report and review of the literature. *Surg Infect (Larchmt)*. 2013, 13:63-66. [10.1089/sur.2010.093](https://doi.org/10.1089/sur.2010.093)
7. Jover-Sáenz A, Cerezo-Esforzado E, Barcenilla-Gaite F, Garrido-Calvo S, Porcel-Pérez JM : Leclercia adedecarboxylata cholecystitis in a patient with metabolic syndrome. *Surg Infect (Larchmt)*. 2008, 9:411-412. [10.1089/sur.2007.068](https://doi.org/10.1089/sur.2007.068)
8. Broderick A, Lowe E, Xiao A, Ross R, Miller R : Leclercia adedecarboxylata folliculitis in a healthy swimmer-An emerging aquatic pathogen?. *AAD Case Rep*. 2019, 5:706-708. [10.1016/j.jdcr.2019.06.007](https://doi.org/10.1016/j.jdcr.2019.06.007)
9. Riazzi C, López-Cerero L, Rojo-Martín MD: First report of NDM-1-producing clinical isolate of leclercia adedecarboxylata in Spain. *Diagnostic microbiology and infectious disease*. *Diagn Microbiol Infect Dis*. 2017, 88:268-270. [10.1016/j.diagmicrobio.2017.04.013](https://doi.org/10.1016/j.diagmicrobio.2017.04.013)
10. Thevis M, Schrader Y, Thomas A, Sigmund G, Geyer H, Schänzer W: Analysis of confiscated black market drugs using chromatographic and mass spectrometric approaches. *J Anal Toxicol*. 2008, 32:232-240. [10.1093/jat/32.3.232](https://doi.org/10.1093/jat/32.3.232)
11. Blackstone EA, Fuhr JP, Pociask S: The health and economic effects of counterfeit drugs . *Am Health Drug Benefits*. 2014, 7:216-224.
12. Midgley SJ, Heather N, Best D, Henderson D, McCarthy S, Davies JB : Risk behaviours for HIV and hepatitis infection among anabolic-androgenic steroid users. *AIDS care*. 2000, 12:163-170. [10.1080/09540120050001832](https://doi.org/10.1080/09540120050001832)
13. Ip EJ, Yadao MA, Shah BM, & Lau B : Infectious disease, injection practices, and risky sexual behavior among anabolic steroid users. *AIDS care*. 2016, 28:294-299. [10.1080/09540121.2015.1090539](https://doi.org/10.1080/09540121.2015.1090539)